Imaging tumour hypoxia with positron emission tomography
about
Effects of Charged Particles on Human Tumor CellsImaging Modalities to Assess Oxygen Status in GlioblastomaComputational Model for Tumor Oxygenation Applied to Clinical Data on Breast Tumor Hemoglobin Concentrations Suggests Vascular Dilatation and CompressionTargeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?Pharmacokinetic Analysis of Dynamic 18F-Fluoromisonidazole PET Data in Non-Small Cell Lung Cancer.(18)F-fluoromisonidazole kinetic modeling for characterization of tumor perfusion and hypoxia in response to antiangiogenic therapy.Molecular mechanisms of hypoxia in cancer.Self-Monitoring Artificial Red Cells with Sufficient Oxygen Supply for Enhanced Photodynamic TherapyNanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma.Assessment of intratumor hypoxia by integrated 18F-FDG PET / perfusion CT in a liver tumor model.Biological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal Liver Metastases (CRLM): Looking Beyond the Tumor Margin.Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times.Evaluation of the association between HIF-1α and HER-2 expression, hormone receptor status, Ki-67 expression, histology and tumor FDG uptake in breast cancer.Assessing Tumor Oxygenation for Predicting Outcome in Radiation Oncology: A Review of Studies Correlating Tumor Hypoxic Status and Outcome in the Preclinical and Clinical SettingsHypoxia imaging and radiotherapy: bridging the resolution gap.Tumor hypoxia: a new PET imaging biomarker in clinical oncology.Hypoxia in cervical cancer: from biology to imaging.Hypoxia-responsive nanocarriers for cancer imaging and therapy: recent approaches and future perspectives.Biological imaging in clinical oncology: radiation therapy based on functional imaging.Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy.Correlation of pretreatment 18F-FDG PET tumor textural features with gene expression in pharyngeal cancer and implications for radiotherapy-based treatment outcomes.Immunohistochemical studies and fluorodeoxyglucose uptake on positron emission tomography in pharyngeal cancer for predicting radiotherapy-based treatment outcomes.Hypoxia induces copper stable isotope fractionation in hepatocellular carcinoma, in a HIF-independent manner.Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in 18fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer.A role for dynamic contrast-enhanced magnetic resonance imaging in predicting tumour radiation response.FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas.KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation.[18F]Fluoromisonidazole PET in rectal cancer.Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer.PET/CT is a cost-effective tool against cancer: synergy supersedes singularityEPR Oximetry Sensor-Developing a TAM Derivative for In Vivo Studies.Applications of "Hot" and "Cold" Bis(thiosemicarbazonato) Metal Complexes in Multimodal Imaging.Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX.A bioreducible N-oxide-based probe for photoacoustic imaging of hypoxia.Impact of tissue transport on PET hypoxia quantification in pancreatic tumours.The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma.The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.Copper complexes with dissymmetrically substituted bis(thiosemicarbazone) ligands as a basis for PET radiopharmaceuticals: control of redox potential and lipophilicity.Synchronous delivery of oxygen and photosensitizer for alleviation of hypoxia tumor microenvironment and dramatically enhanced photodynamic therapy.
P2860
Q26767252-DFDD9796-3A6B-4779-95C7-8F1E1653580FQ26782708-1CFCC716-FF83-4E54-900C-82252D544E72Q27327081-07D67141-7F31-43DF-9FDE-05FD333DFC8BQ30388849-9B8D0460-7A07-415F-AAD2-C0DBA92C55F0Q31165401-31151172-2102-4604-AA21-CAB895B19993Q32179417-67D963DE-5F7C-4C86-ABC4-723E5CF3729FQ33705108-2111D0BD-89D0-4B44-AD12-5B3D3E9C778DQ35961483-9C1CE2CD-F812-4416-B78C-BA25673EF731Q36031889-6F676F32-B6A4-4BB6-A1B5-D9AB098DB509Q36298320-D6415B48-42C1-4680-AA07-9ED0E40EE7B8Q36653705-6EA0A5EC-44DB-4EE8-A8CE-03C764546C9AQ37161068-5670DDF5-5BFB-4676-BDB0-8CF1A81E0BD2Q37407235-EB7DA37A-FCD7-4863-9EFC-9C8260D96DF5Q37604088-C2D1FFB2-B145-414A-AEAF-FF221D308C59Q38400842-9EAD1B59-041A-483A-8385-C35F045CA57CQ38411275-8EB1B706-4F84-4DF3-B3AF-83E27DA78653Q38643119-EF564C97-28F0-489C-A5C1-1450C081A87FQ38844453-F2AB5DF4-5927-49DD-B324-26641512A804Q38887987-95757203-925E-4C9F-99BD-3647F925D0E8Q39051286-A1301089-64C3-4648-AB44-CD327A4C7B8DQ39061401-F90F5879-FFC9-460E-A4C7-19756772C32CQ39079577-ED42CF72-3AE3-42D4-A522-4CE35857B945Q39268251-F9C972B6-9A20-4274-A743-306C007AA1DFQ39513724-9197AD2D-B3FD-474E-9A82-2ADF5E648A39Q39677481-D7D19DA8-23C3-4948-9EAD-7EA3B7ED81A4Q39799440-33CA412B-045E-4C07-8DF5-2BFEC39AAF45Q41581761-5BAF65FB-6F8D-4457-93B2-2E4B7C9680A4Q42107713-953A743C-CE23-4613-88AE-1A3E0DC98F95Q42121596-FC530D9D-BB83-40DB-835A-908EDE79C5F1Q42121913-E5B78FD1-F36D-4C34-8DD0-C1BBDEABC72EQ42388521-A20645EA-569F-4A3E-A78A-F45A26EC167CQ46176263-3A344FFE-B285-4C7E-963F-BA0A932794B0Q46552901-8E47BEDE-52F6-4310-A28C-EC335987B8C0Q47097799-64C4E792-E1C2-496C-8F6A-11FA84AA27ADQ47103167-207C162D-1F8D-4684-A80A-12556DC7A3EFQ47115519-3E6E4732-ED26-4EEC-A231-0903EB520CD2Q47318963-B2576E43-253B-424D-B9F7-069EB962A89AQ47763534-ECCABE6B-1B96-4BEE-A5D7-DD78300719CFQ48544553-F3D1A0CB-2622-4064-A3F7-E1ADA76F6979Q49816412-397A8A4F-A6BC-4977-B7EB-68AA1E68E461
P2860
Imaging tumour hypoxia with positron emission tomography
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Imaging tumour hypoxia with positron emission tomography
@ast
Imaging tumour hypoxia with positron emission tomography
@en
Imaging tumour hypoxia with positron emission tomography
@nl
type
label
Imaging tumour hypoxia with positron emission tomography
@ast
Imaging tumour hypoxia with positron emission tomography
@en
Imaging tumour hypoxia with positron emission tomography
@nl
prefLabel
Imaging tumour hypoxia with positron emission tomography
@ast
Imaging tumour hypoxia with positron emission tomography
@en
Imaging tumour hypoxia with positron emission tomography
@nl
P2093
P2860
P50
P3181
P356
P1476
Imaging tumour hypoxia with positron emission tomography
@en
P2093
P2860
P2888
P304
P3181
P356
10.1038/BJC.2014.610
P407
P5008
P577
2015-01-20T00:00:00Z
P5875
P6179
1050909655